Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

Over the past decade, neurodegenerative research and development has responsibly answered a foundational question: can we ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at the ...

In another major setback for abortion care in the US, a US court has issued an order restricting the distribution of ...

In addition to the three NPVs, the FDA also announced the approval of an IND submission for DemeRx, which is investigating ...

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's ...

In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral ...

Moderna saw its first-quarter revenues nearly triple to $389 million compared to the same period of 2025, with international ...

In a statement, Prime Minister Keir Starmer said the "significant investment" had been "made possible by the pharmaceutical ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...

As a tech lover, I soak it all in and leave inspired about what’s next. This was the case recently when I attended Google ...